Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer

Multi Center Double Blind Study Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00553878

Acronym

AVIAS

Enrollment

100

Registered

2007-11-06

Start date

2007-03-31

Completion date

2012-12-31

Last updated

2016-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

Patient on an intermittent androgen deprivation protocol for biochemical recurrence after radical local therapy for prostate cancer,the addition of continuous dutasteride treatment, significantly prolongs the duration of the off treatment interval and time to androgen independence.

Detailed description

The study is to assess the effect of therapy with repeat oral daily dosing of dutasteride 05 mg on the length of the off treatment interval in men receiving intermittent androgen therapy for localized prostate cancer.

Interventions

DRUGDutasteride

dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

MALE

Age

45 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Able to give informed consent * Age\_\>45and\<\_80 * Histological confirmed adenocarcinoma of prostate * Has received external beam radiation,brachytherapy or radical prostatectomy for the treatment of prostate ca * Candidate for intermittent androgen ablation * Minimum of 3 PSA values above nadir taken at least 1 month apart * Serum testosterone \>\_250ng/dl,ECOG 0 or 1 * Negative bone scan within 12 months of visit 1 * Able to swallow and retain oral medication

Exclusion criteria

* Previous treatment with chemotherapy * Hormonal therapy with in last year * Glucocorticoid with in last 3 months * LHRH analogues with in previous year * Ketoconazole * Non Steroidal anti-androgens with in previous year * Concurrent or previous use of Finasteride Dutasteride 5a reductase inhibitor anabolic steroids * Over the counter or herbal prep such as saw palmetto selenium or vitamin E within last year * May not be receiving any other investigational drug with in last 30 days * Evidence of distant metastases * Has received adjuvant or neoadjuvant ablation in past 12 months * Unstable serious co-existing medical condition * Abnormal liver and kidney functions * Previous malignancy not including curative treated basal cell carcinoma of skin with in 5 years and bladder cancer with in past 2 years * Known hypersensitivity to any 5a-reductase inhibitor or to any drug chemically related to dutasteride * Known hypersensitivity to bicalutamide.

Design outcomes

Primary

Measure	Time frame
To assess whether repeat oral once daily dosing of dutasteride 0.5mg increases the length of the off treatment interval in men receiving intermittent androgen ablation therapy for localized prostate cancer	2 Years

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026